FL-MHPS
15.4.2020 12:02:05 CEST | Business Wire | Press release
Mitsubishi Hitachi Power Systems’ (MHPS) J-Series gas turbine installed fleet today reached one million hours of commercial operation, nearly double that of similar sized gas turbines from competitors. This gas turbine series — the company’s largest and most advanced — leads the industry with reliable, efficient power generation and flexibility to meet rigid new standards for reduced carbon emissions. Introduced in 2011, the J-Series delivers an industry-leading overall reliability of 99.5% and an efficiency greater than 64%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200415005220/en/
Forty-three J-Series gas turbines are in commercial operation, and total ordered capacity exceeds 25 GW globally. One hundred units have been technically selected in Brazil, Canada, Japan, Mexico, Peru, South Korea, Taiwan, Thailand, and the United States.
Donald Schubert, Principal at SHL Consulting LLC and former Senior Vice President of Marshes Global Power Practice, said, “MHPS continues to embrace proven technology throughout their gas turbine fleet. The insurability of the operating units remains at an all-time high for MHPS large frame machines.”
In many parts of the world, the J-Series gas turbine frequently replaces retired coal-fired power generation or is installed as an alternative to coal-fired power generation. Compared to the same size coal-fired power plants, one million J-Series operating hours has resulted in CO2 emissions reduction of 270 million tons. This is equivalent to CO2 emissions from 1,346,918 railcars of coal burned.
Ken Kawai, President and CEO of MHPS said, “As we reflect on the important milestone of achieving one million operating hours with our J-Series gas turbine, we know the most important part of that accomplishment is that we ran all those hours with 99.5% reliability. It all started with T-Point, our own combined cycle power plant in Takasago, Japan. Our extreme reliability is not by good luck. It is because we test the durability and reliability of every new technological advancement for 8,000 hours before shipping it to our customers. We have now built a second T-Point, T-Point 2, where our latest advancement, the cutting-edge air-cooled 60 Hz JAC, has just synced to the grid and achieved full load. Step-by-step, we have developed the largest, most reliable and most fuel-efficient gas turbine in the world.”
Recent innovations to the J-Series target further reductions in carbon emissions. Last month the company received an order from the Intermountain Power Agency, in Delta, Utah, for two JAC gas turbines capable of using up to 30% renewable hydrogen fuel. Eventually, these turbines will be capable of using 100% renewable hydrogen fuel. The 30% hydrogen system will reduce carbon emissions by more than 75% compared to the same size coal-fired power plant, and the 100% hydrogen system will eliminate carbon emissions entirely. MHPS is also developing grid-scale renewable hydrogen production and storage through the Advanced Clean Energy Storage (ACES) project in Delta, Utah.
Paul Browning, President and CEO of MHPS Americas and newly appointed Chief Regional Officer for Europe, Africa and the Middle East, said, “Going forward, every gas turbine MHPS sells globally will have renewable hydrogen fuel capability. This allows our customers to purchase a natural gas power plant today, and convert it over time into a renewable energy storage facility. This gives plant operators flexibility now and into the future to choose what mix of natural gas power generation and renewable energy storage best meets the needs of their electrical grids. We are providing the power generation and storage solutions that enable our customers to combat climate change and advance human prosperity. This is a Change in Power.”
About Mitsubishi Hitachi Power Systems Americas, Inc. Mitsubishi Hitachi Power Systems Americas, Inc. (MHPS Americas), headquartered in Lake Mary, Florida, employs more than 2,000 power generation and energy storage experts and professionals. Our employees are focused on empowering customers to affordably and reliably combat climate change while also advancing human prosperity. MHPS Americas’ expertise includes natural gas, steam, aero-derivative, geothermal, and distributed renewable power generation technologies and services, along with renewable hydrogen and battery energy storage systems, environmental control systems solutions, and digital solutions enabling autonomous operations and maintenance of power assets throughout North and South America. MHPS Americas is a subsidiary of Mitsubishi Hitachi Power Systems (MHPS), a joint venture between Mitsubishi Heavy Industries, Ltd. and Hitachi, Ltd. integrating their operations in power generation systems. Learn more about MHPS by visiting www.changeinpower.com . |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200415005220/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom